NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Finnrick
Free Test

Vendor Intelligence Report: Certified Peptides

Published 11 Nov 2026. 39-page investigative report on who is behind Certified Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Certified Peptides is not a one-score vendor. Across 64 Finnrick lab tests, the headline outcome is 12 pass / 6 fail, for an overall pass rate of 19%. The spread matters more than the headline: Ipamorelin and Tirzepatide carry the cleanest small-sample signal, while CJC-1295 and Tesamorelin are lot-verification problems rather than routine reorders. Ratings compress under stricter grading, so Appendix A is essential before choosing a product.

The documentation picture is unusually mixed. Certified-Pep publishes a large COA library, and Vanguard’s lab-operated hub authenticates selected certificates. Those are real traceability positives. But the GLP3-R 120 mg record has a vendor-image-versus-lab-PDF amount mismatch, the Texas cGMP manufacturing chain is unnamed, and reviewed public pages did not identify who controls sourcing, QA review, or batch release. That is a visibility gap, not proof of absent expertise.

The legal and channel records are the sharper buyer issue. Companies House filings tie a same-name UK company, a sole-controller record, a Rochester address trail, a default registered office, and a first Gazette strike-off notice to the brand’s orbit, while the retail site still does not name the checkout seller. The report also separates useful Reviews.io/Google fulfillment evidence from weaker social proof: removed Trustpilot, vendor-administered reviews, self-ranking amplified as news, a public staging copy, lookalikes, and Everflow affiliates.

Inside the full report:

  • Finnrick product guidance, methodology-divergence charts, and Appendix A laboratory data for all seven tested products
  • Companies House filings, strike-off timeline, registered-office changes, and the Rochester address trail
  • Vanguard hub verification, R30 documentation, and the GLP3-R 120 mg COA mismatch analysis
  • Purchase-channel map covering certified-pep.com, gigboosters.com, content sites, lookalikes, and the Vanguard hub
  • Review and promotion analysis across Reviews.io, Google, Trustpilot, PepReviewPro, Everflow, paid posts, and coupon/referral pages

Risk assessment

  • CJC-1295 and Tesamorelin product-quality risk — high: Finnrick records CJC-1295 at 1 pass / 2 fail (30.47%) and Tesamorelin at 0 pass / 2 fail (45.16%); avoid without target-lot verification.
  • Retatrutide / GLP3-R lot-verification risk — medium: Retatrutide is 3 pass / 2 fail (73.1%) and the GLP3-R 120 mg lot record has a vendor-image 100 mg vs lab-PDF 120 mg discrepancy.
  • Legal-operator and corporate-continuity risk — high: The site names no legal seller; the likely entity, CERTIFIED-PEP LTD, is in active proposal to strike off with a default registered office and overdue confirmation statement.
  • Copycat and channel-confusion risk — medium: A live staging copy (gigboosters.com), branded content site, lookalike domains, and no public authorized-channel list make genuine-channel verification a buyer burden.
  • Affiliate-promotion and social-proof integrity risk — medium: Everflow pays 20% on first orders; code/referral promotion is widespread, Trustpilot is removed while still claimed, and PepReviewPro is vendor-administered.